Datapoint: Idorsia’s Quviviq Approved for Insomnia

The FDA on Monday approved Idorsia Ltd’s Quviviq for the treatment of adults with insomnia. The dual orexin receptor antagonist (DORA) will have to face off against Merck’s Belsomra and Eisai Co.’s Dayvigo, two leading DORAs in the insomnia market basket. Belsomra currently holds covered or better status for 87% of all insured lives under the pharmacy benefit, compared to Dayvigo’s 65%.

SOURCE: MMIT Analytics, as of 1/12/2022

0

0

0 Comments

0

0

• Datapoint